Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
35 /100
MEDIUM RISK
Score updated Oct 13, 2026

RLAY — Relay Therapeutics, Inc. Dilution Risk Tracker

Track RLAY dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track RLAY — Get alerts when the score changes →

As of October 13, 2026, Relay Therapeutics, Inc. (RLAY) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. Relay Therapeutics, Inc. has a market capitalization of $3.94B, 219.14M shares outstanding, 244 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
26
💰 Cash Runway
65
📊 Float Risk
32
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 7%
💰 Capital Raise model 15%
• Under 12 months cash (6mo)
🔔 Track RLAY — Get forecast alerts →

Market Data

Market Cap$3.94B
Shares Outstanding219.14M
Float136.02M
Cash$121.19M
Debt$31.57M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore35/100DilutionWatch score record
Shares Outstanding219.14MVerified float table or market cache
Public Float136.02MVerified float table or market cache
Market Cap$3.94BMarket data cache
Cash Runway6.0 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 3.

Recent SEC source mix: 4 2, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 23.5% shares (2026Q1 vs prior)
244 institutional holders · 217.58M shares
#1 SB INVESTMENT ADVISERS (UK) LTD 27.90M shares
#2 PERCEPTIVE ADVISORS LLC 19.50M shares
#3 Commodore Capital LP 17.00M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest46.75M
Days to Cover12.6
% of Float34.4%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2023-02-23
4 INSIDER TRANSACTION 2026-04-09
4 INSIDER TRANSACTION 2026-03-11
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual RLAY Dilution Snapshot

Relay Therapeutics, Inc. (RLAY) has a DilutionScore of 35/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

RLAY's DilutionScore has held steady at 35/100 (Medium risk) for 89 consecutive days across the tracked period.

Period Score Risk Level Duration
Jul 16 – Oct 13, 202635/100MEDIUM89 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

RLAY shares outstanding have increased 20.0% from 178.73M (Mar 2026) to 214.50M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 27, 2026214.50M136.02M▲ 0.01%
May 25, 2026214.50M136.00M▲ 5.96%
May 18, 2026191.59M128.36M▲ 10.74%
May 10, 2026191.59M115.91M▲ 0.83%
May 08, 2026191.59M114.96M▲ 7.19%
May 06, 2026191.34M107.26M▲ 0.10%
May 04, 2026191.34M107.15M▼ 0.12%
Apr 26, 2026178.73M107.28M▲ 4.07%
Apr 18, 2026178.73M103.09M▲ 0.02%
Apr 17, 2026178.73M103.07M▲ 10.04%
Mar 27, 2026178.73M93.67M▲ 0.02%
Mar 23, 2026178.73M93.65M▼ 9.13%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track RLAY Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment RLAY files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking RLAY — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for RLAY
RLAY FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.